June 2014 Blog Posts (30)

Colorectal Cancer Patients Experience Abnormalities in Processing Chronic Pain - may Lead to Problems in Pain Processing of any Kind in the Future, Study Shows

Spanish researchers from the University of Granada have discovered that colon cancer survivors are more likely to suffer future lesions related with pain in the back and lower abdomen than healthy individuals of the same gender and age. The researchers noted that this group of patients present a series of abnormalities in the abdominal wall architecture — the site of surgery in cancer treatment. Furthermore, these patients have specific…

Continue

Added by Editorial Team on June 27, 2014 at 12:30am — No Comments

New Nanoliposomal Drug Shows Survival Benefit in Metastatic Pancreatic Cancer

Results from a study presented at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona, Spain, shows that adding a novel novel long-circulating nanoliposomal formulation of irinotecan (nal-IRI) called MM-398 to standard treatment for metastatic pancreatic cancer patients who have already received gemcitabine improves survival.

MM-398, under development by Merrimack Pharmaceuticals, Inc (Cambridge, Mass) is being evaluated in several clinical trials including a…

Continue

Added by Editorial Team on June 26, 2014 at 10:30am — No Comments

Pancreatic Cancer Risk Lowered by Continued Use of Low-dose Aspirin, Study Shows

A study funded by the National Cancer Institute and published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research shows that the longer a person took low-dose aspirin, the lower his or her risk for developing pancreatic cancer.

"We found that the use of low-dose aspirin was associated with cutting the risk of pancreatic cancer in half, with some evidence that the longer low-dose aspirin was used, the lower the risk,"…

Continue

Added by Editorial Team on June 26, 2014 at 1:30am — No Comments

New Toxicology Study Shows Decreased Mortality and Better Tolerability of ADC Generated with SMARTag Platform vs. Conventional Conjugation Technology

Results of an in vivo toxicology study, demonstrates that an Antibody Drug Conjugate or ADC generated using the proprietary SMARTag™ platform has a better toxicity profile than a conventional ADC. The study, conducted in a rat model by scientists at Redwood Bioscience, Inc.(Emeryville, CA), a company developing precision protein-chemical engineering technology to produce next-generation antibody-drug conjugates and other…

Continue

Added by Editorial Team on June 24, 2014 at 7:00pm — No Comments

Independent Study Shows Clinical Outcomes of Patients Assessed with both MammaPrint and Oncotype DX

Genomic assays are used to analyse a sample of breast cancer tissue in order to predict the risk of the various cancers, including breast as well as colon/colorectal cancer. While there are a number of genomic assays available, there has never been a real comparison between two of the major commercially available genomic assays, Oncotype DX®.(Genomic Health, Redwood City, CA, USA) and MammaPrint®,  BluePrint® and TargetPrint® (Agendia; Irvine, CA, USA/Amsterdam, The…

Continue

Added by Editorial Team on June 21, 2014 at 11:00pm — No Comments

Racial Disparities in Breast Cancer

According to numerous studies, disparities in breast cancer diagnosis and survival rates between black and white women have not improved in the past two decades. However, the use of sentinel lymph node biopsy or SLNB to stage early breast cancer increased in both black and white women from 2002 to 2007. These increased rates, remained lower in black than white patients, a disparity that contributed to disparities in the risk for lymphedema, a common swelling of the arm after breast…

Continue

Added by Editorial Team on June 18, 2014 at 10:00pm — No Comments

Cholesterol-fighting Compound Halts Progression of Breast Cancer

A new study funded by a grant from the Department of Defense Breast Cancer Program and the National Institutes of Health and conducted by Researchers at the University of Missouri, shows that the oxidosqualene cyclase inhibitor RO 48-8071, a compound initially developed by Roche Pharmaceuticals as a cholesterol-fighting molecule, not only halts the progression of breast cancer, but also can kill the cancerous cells. The findings were published in the May 31, 2014 issues of Breast Cancer…

Continue

Added by Editorial Team on June 17, 2014 at 4:00pm — No Comments

Successful Outreach Program Doubles Colorectal Screening in Minority and Low-income Communities

Colorectal cancer is a relatively common disease which leads to significant morbidity and mortality. According to data from the World Health Organization (WHO) GLOBOCAN database, the incidence of CRC varies around the world, with the highest incidence rates in Australia and New Zealand, Europe and North America, and the lowest rates are found in Africa and South-Central Asia. With over 1.2 million new cases and 608,700 deaths, colorectal cancer remains, however, the third most commonly…

Continue

Added by Editorial Team on June 16, 2014 at 3:00pm — No Comments

Majority of Specialists Involved in Prostate Cancer Treatment Don't Recommend Active Surveillance for Low-risk Patients

A study published in the July 2014 issue of Medical Care suggests that most prostate cancer specialists who treat prostate cancer agree that active surveillance is an effective option. However, most phycisians do not recommend it for their own low-risk patients, even if this would be appropriate. Instead, the researchers found that the majority of physicians recommend treatments performed by their own specialty.

Clinicians’ framing of disease management options is an…

Continue

Added by Editorial Team on June 16, 2014 at 10:00am — No Comments

Scientists Discover Important New Biomarker Which may Provide Key to Overcome Resistance to HER2 Targeted Therapies

A team of scientists from the School of Pharmacy & Pharmaceutical Sciences, at the Trinity College in Dublin, Ireland, in collaboration with St. Vincent's University Hospital, Dublin City University and Royal College of Surgeons in Ireland, have made a significant discovery of a new biomarker which may help overcome resistance to newer and more targeted anti-cancer drugs, such as trastuzumab (…

Continue

Added by Editorial Team on June 15, 2014 at 9:30pm — No Comments

Anti-malaria Drug Hydroxychloroquine Restores Anti-estrogen Sensitivity toTamoxifen-resistant Breast Cancer

About 50% of estrogen receptor-positive or ER+ breast cancers treated with receptor-α or ERα-targeted therapies, including tamoxifen (Nolvadex®; AstraZeneca/Soltamox®/DARA BioSciences) and fulvestrant (Faslodex®; AstraZeneca) develop resistance to these…

Continue

Added by Editorial Team on June 15, 2014 at 10:30am — No Comments

Does Preoperative Genetic Testing Affect Surgical Decision Making in Women Diagnosed with Breast Cancer?

The impact of an initial diagnosis of breast cancer can be devastating. After dealing with the emotional impact of the diagnoses and processing new and unfamiliar information, difficult decisions need to be made. One of the most difficult decisions is related to the extend of the surgical treatment required: is a lumpectomy better than a mastectomy with reconstructive surgery? The decision is not easy. Knowing the risk of recurrence may help in making the right decision. Many women…

Continue

Added by Editorial Team on June 14, 2014 at 2:30pm — No Comments

Childhood Cancer Survivors Face Ongoing Medical Problems Years After Cancer Treatment

Findings from a study to be published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research shows that, compared with the general population, survivors of childhood cancers are more often hospitalized and for longer durations because of blood disorders and other problems, many years after cancer treatment was…

Continue

Added by Editorial Team on June 12, 2014 at 1:00am — No Comments

Study Confirms Ibrutinib Significantly Delays Disease Progression and Extends Survival for Patients with Resistant or Relapsed CLL

Early findings from the phase III RESONATE study, presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), being held May 30 - June 3, 2014 in Chicago, Ill, indicates that ibrutinib (Imbruvica™; Pharmacyclics/Janssen Biotech), an anticancer drug targeting B-cell malignancies approved by the U.S. Food and Drug Administration (FDA) in November 2013 for the treatment of mantle cell lymphoma and in…

Continue

Added by Editorial Team on June 3, 2014 at 11:00pm — No Comments

Discontinuing Certain Medications at End of Life May Improve a Patient's Health Related Quality of Life

It was a question that needed an answer. Is it safe to discontinue statins for a patient with less than a year to live? Does the risk outweigh the benefits when medications for optimal management of longstanding medications prescribed for comorbid illness are discontinued?

Findings from a federally funded, randomized study, seems to indicates that it is indeed safe to stop statin therapy in this group of patients. The study results show that discontinuing statins did not…

Continue

Added by Editorial Team on June 3, 2014 at 10:00pm — No Comments

Some Patients with HPV-positive Oropharyngeal Cancer may benefit from Lower-does Radiation Therapy

A phase II study funded by the National Institutes of Health (NIH) shows that certain HPV-positive oropharyngeal cancer (HPV-POC) patients can safely receive a lower-dose radiation therapy. The therapy is using a new approach that customizes radiation dose based on response to induction chemotherapy and other prognostic factors. These findings showed that lowering the dose of radiation therapy did not compromise outcomes. In 95% of all…

Continue

Added by Editorial Team on June 3, 2014 at 8:30pm — No Comments

Study Shows that Early, Phone-based Palliative Care helps Improve Quality of Life (QoL) for Caregiver

Family caregivers play a crucial role in providing palliative care. However, numerous studies have shown that the Quality of Live of family caregivers may be negatively impacted. They may suffer from both reduced emotional functioning as well as a generally lower quality of life compared to that of the general population. While the number of studies looking at family caregivers, studies have shown that especially female caregivers have lower functional values and stronger symptoms of…

Continue

Added by Editorial Team on June 3, 2014 at 8:30pm — No Comments

Proof-of-Principal of Experimental Personalized Strategy for Advanced Cervical Cancer Shows Striking Results

A new type of personalized immunotherapy, known as adoptive T cell therapy shows striking results in several women with advanced cervical cancer. In a small, federally funded Phase II study which was supported by the National Cancer Institute and the National Institutes of Health, two patients with advanced cervical cancer and widespread metastases had complete remissions after a single treatment with the HPV-targeted T cells. These two patients have been cancer free for nearly a…

Continue

Added by Editorial Team on June 3, 2014 at 1:30pm — No Comments

Study Confirms Goserelin Helps Preserve Fertility Among Women Receiving Chemotherapy for Hormone Receptor-negative Breast Cancer

Results from a federally funded phase III clinical trial presented at the 50th Annual Meeting of the American Society of Clinical Oncology shows that adding a hormone suppressing drug called goserelin (Zoladex®; AstraZeneca), to standard chemotherapy may be an effective method of preserving fertility among women with early-stage hormone receptor-negative breast…

Continue

Added by Editorial Team on June 3, 2014 at 12:30pm — No Comments

Large Phase I Study Shows PD-1 Targeting Antibody MK-3475 has High and Long-lasting Activity Against Metastatic Melanoma

Findings from a large phase I study of 411 patients with advanced melanoma show that the PD-1 (programmed death-1 or programmed cell death-1/PCD-1) targeting antibody MK-3475 presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) held May 30, June 3, 2014 in Chicago, Ill, shows that the new trial drug yields long-term responses in a high percentage of patients.

Researchers have found that a…

Continue

Added by Editorial Team on June 2, 2014 at 10:00pm — No Comments

Monthly Archives

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2005

2004

2001

Register for free to view all the Onco'Zine - The International Oncology Network content:

ADVERTISEMENT/MEDIA PARTNER

Onco'Zine is present here

Bookmark / Share

CONNECT WITH US AND

JOIN THE CONVERSATION


© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+